| Document |
Document Title |
|
WO/2018/012845A1 |
The present application relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting element comprising the same.
|
|
WO/2018/009488A1 |
The application describes methods for making a deuterated dextromethorphan of Formula (I), deuterated dextromethorphan produced by these methods, and pharmaceutically acceptable salts thereof.
|
|
WO/2018/009007A1 |
The present application provides: a heterocyclic compound capable of greatly improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light emitting device; and an organic light emitting device h...
|
|
WO/2018/009009A1 |
The present application provides a heterocyclic compound capable of remarkably improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device, and an organic light-emitting device...
|
|
WO/2018/005731A1 |
A lactam-functionalized polymer is disclosed. The lactam-functionalized polymer includes lactam-functionalized polyacetal polyether, polyhemiaminal polyether or polyaminal polyether. The applications of the lactam-functionalized polymer ...
|
|
WO/2017/223229A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2017/218191A1 |
The present invention includes compounds, compositions and methods that are useful for preventing or treating melanoma or any other Myc-expressing cancer in a subject. In certain embodiments, the compounds comprise estrogen (including es...
|
|
WO/2017/218950A1 |
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease o...
|
|
WO/2017/197045A1 |
A highly convergent biomimetic synthesis of a complex polycyclic scaffold has been successfully implemented. From these efforts, compounds having a structure of Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer ...
|
|
WO/2017/176510A1 |
An electro-polarizable compound has a general formula: (I) Core1 is an aromatic polycyclic conjugated molecule. R1 and R1' are electron donor and acceptor groups, respectively; m, m' can be 0, 1, 2, 3, 4, 5, 6, but not m=m'=0. R2 is an i...
|
|
WO/2017/176509A1 |
An electro-polarizable compound has a general formula: _ _ | ____________ | | | | | | | [R1]m | | <-NLE | | | | | | | | [ Core1 ]-----|-[Core2]n |-[R4]k (I) | |___ |_______| | | | | | | | [R2]p [R3]s | |_ _| Core1 is an two-dimensional f...
|
|
WO/2017/176491A1 |
A composite organic compound characterized by polarizability and resistivity that has a general structural formula (I) where C is a chromophore fragment, P is an optionally connected rylene fragment, D and A are electron donating and acc...
|
|
WO/2017/173105A1 |
Reagents for stabilizing the nucleic acids of a biological cell, compositions, kits and methods of use thereof are described. The stabilization reagents may prepare the nucleic acids within the biological cell for storage and preserve th...
|
|
WO/2017/157322A1 |
Provided are a compound represented by formula I, a raceme thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof, a preparation method therefor, a pharmaceutical composition comprising th...
|
|
WO/2017/146400A1 |
The present invention relates to a compound for detecting phosgene and DCP (diethyl chlorophosphate) and a composition for detecting phosgene and DCP (diethyl chlorophosphate) comprising the said compound. More precisely, the compound fo...
|
|
WO/2017/136616A1 |
Indenoisoquinoline topoisomerase I (Topi) inhibitors are a novel class of anticancer agents. The present invention discloses series of prodrugs of two indenoisoquinoline compounds currently in clinical trials as a potential treatment for...
|
|
WO/2017/125318A1 |
The invention relates to a novel process for preparing polyfluoroalkylated quinolines from ketimines in the presence of fluoroalkylamino reagents.
|
|
WO/2017/124080A1 |
Disclosed herein are methods and drug compositions for treating Lyme disease and post- treatment Lyme disease syndrome (PTLDS) or chronic Lyme disease (CLD). In one embodiment, a method of treating a subject with Lyme disease involves ad...
|
|
WO/2017/120559A1 |
Pharmaceutical compositions of muscarinic acetylcholine receptor antagonists suitable for administration via a dry powdered inhaler and methods of using the compositions for treating respiratory disease are provided.
|
|
WO/2017/117960A1 |
A compound and a preparation method therefor, and an organic electroluminescent device. The compound has a general formula as shown by formula I, wherein the R group is a substituent containing N, O or S atoms. The compound is applied to...
|
|
WO/2017/115649A1 |
The present invention addresses the problem of providing a compound which enables the formation of a cured article having a small Abbe's number and also having high abnormal dispersion. The present invention also addresses the problem of...
|
|
WO/2017/117347A1 |
A method of treating schizophrenia includes parenterally administering to a subject a pharmacological agent that inhibits presynaptic glutamate release, modulates postsynaptic glutamate response, or both.
|
|
WO/2017/108152A1 |
The present invention relates to compounds according to formula (I), which are suitable for use in electronic devices, preferably organic electroluminescent devices.
|
|
WO/2017/112777A1 |
Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are compositions and methods for treating cancer and inflammatory disease.
|
|
WO/2017/106930A1 |
The present invention describes non-cyclic enaminoketone compounds and their applications relating to absorption electromagnetic energy, in particular UV radiation.
|
|
WO/2017/102063A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2017/102014A1 |
The present invention deals with new flavivirus inhibitors, compositions comprising said inhibitors and methods for the treatment of disorders related to a viral infection, such as a disease due to a flavivirus infection, comprising admi...
|
|
WO/2017/093519A1 |
The invention relates to dextrorphan-derivatives, pharmaceutical compositions and pharmaceutical dosage forms containing such dextrorphan-derivatives as well as the use of those dextrorphan-derivatives and/or compositions for treating an...
|
|
WO/2017/086832A1 |
The invention relates to substituted N2-(4-amino-2-methoxyphenyl)-N4-[2-(dimethylphosphinoyl)phen
yl]-5-chloro-pyrimidine-2,4-diamines of general formula (1) and to tautomers, stereoisomers, pharmaceutically acceptable salts and solvates...
|
|
WO/2017/069224A1 |
The present invention pertains to a compound indicated by formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing these. (In the formula, X indicates C (= O), etc., R1 indicates halogen, etc., ...
|
|
WO/2017/053702A1 |
The present disclosure relates to antiscale dispersant compositions. The compositions may include various components. The compositions may be used in connection with gray and/or black water processing in a coal gasification system. The c...
|
|
WO/2017/044730A1 |
The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4- [(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydr
oxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluor
ophenyl)-5- fluoropyridine-2-car...
|
|
WO/2017/035972A1 |
Provided in the present invention are an aromatic amine compound and the preparation and application thereof. The aromatic amine compound having the skeletal structure shown in formula I provided in the present invention can be used in o...
|
|
WO/2017/034814A1 |
Novel photoacid generator compounds are provided. Compositions that include the novel photoacid generator compounds are also provided. The present disclosure further provides methods of making and using the photoacid generator compounds ...
|
|
WO/2016/207083A1 |
The invention relates to haloalkylsulphonamide derivatives of the formula (I) wherein A, W, X, m, n, p, R, R1, R2, R5, R6, R7 and R8 are as defined in the specification. Furthermore, the present invention relates to processes for making ...
|
|
WO/2016/193761A1 |
The present invention provides substituted tridentate benzo[h]quinoline ligands and complexes thereof. The invention also provides the preparation of the ligands and the respective complexes, as well as to processes for using the complex...
|
|
WO/2016/190331A1 |
The purpose of the present invention is to provide an HIV infection inhibitor which can act through a mechanism of action that is different from those of conventional anti-HIV drugs, rarely induces drug resistance, and can inhibit HIVs s...
|
|
WO/2016/181218A1 |
The present invention provides an abuse deterrent oral fixed-dose composition, comprising a stimulant or opioid and an abuse deterrent active, wherein the abuse deterrent active is configured to be bioavailable only when the composition ...
|
|
WO/2016/182840A1 |
The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of th...
|
|
WO/2016/168660A1 |
The present invention is directed to compounds of Formulae I and II which are inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurol...
|
|
WO/2016/164450A1 |
The present invention includes compounds, compositions comprising the same, and methods using the compounds and/or compositions therein, for modulating skin pigmentation in a mammalian subject. In certain embodiments, the compounds and/o...
|
|
WO/2016/151068A1 |
The present invention relates to cyanated compounds of the formula (I) wherein at least one of the radicals R2, R3, R4 and R5 is CN, and the remaining radicals are selected from hydrogen, chlorine and bromine; X is O, S, SO or SO2; m is ...
|
|
WO/2016/147357A1 |
Provided are: a sulfonic acid derivative compound that has high absorbance with respect to light having a wavelength of 365 nm, that has high solubility in an organic solvent, and that exhibits a good acid generation rate; a photoacid ge...
|
|
WO/2016/148809A1 |
Novel photoacid generator compounds are provided. Photoresist compositions that include the novel photoacid generator compounds are also provided. The invention further provides methods of making and using the photoacid generator compoun...
|
|
WO/2016/138158A1 |
Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating...
|
|
WO/2016/138103A1 |
The invention relates to a method for the treatment of neuropsychiatric behavioral symptoms in patients with Alzheimer's Disease wherein the symptoms are selected from the group consisting of anxiety, agitation, aggression, depression, h...
|
|
WO/2016/119031A1 |
The present invention describes a new compound, the method for synthetising same and the use of this compound, as well as a pharmaceutical composition containing said compound. Specifically, the present invention discloses a compound of ...
|
|
WO/2016/109679A1 |
A method of treating symptoms of schizophrenia includes enterically administering to a subject a pharmacological agent that inhibits presynaptic glutamate release, modulates postsynaptic glutamate response, or both. Embodiments herein re...
|
|
WO/2016/103262A2 |
The present invention provides solid crystalline forms of apomorphine free base or a hydrate, solvate, or co-crystals thereof. Such crystalline forms may be advantageous over amorphous forms of apomorphine, e.g., amorphous salt forms suc...
|
|
WO/2016/089951A1 |
The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/composi...
|
